HWKN Stock Analysis: Hawkins | NASDAQ
Specialty Chemicals | NASDAQ, USA | Market Cap: 2.913m USD | 12M Return: -12.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 26.4M
EPS Trend: 84.3%
Qual. Beats: 0
Rev. Trend: 89.2%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Hawkins, Inc. (NASDAQ: HWKN) is a U.S.-based water treatment and specialty ingredients company headquartered in Roseville, Minnesota, operating through three segments: Water Treatment, Food and Health Sciences, and Industrial Solutions. The Water Treatment segment supplies chemicals, filtration equipment, and related services for potable, municipal, industrial, and agricultural water applications. The Food and Health Sciences segment distributes and formulates ingredients such as minerals, vitamins, sweeteners, enzymes, and pharmaceutical salts for nutrition, food, pharmaceutical, and agricultural customers. The Industrial Solutions segment provides bulk industrial chemicals-including acids, alkalis, and related products-to manufacturing, chemical processing, electronics, and surface finishing industries. In addition to distributing third-party chemicals, Hawkins repackages bulk industrial chemicals and performs custom blending, a value-added service that differentiates it from pure chemical manufacturers.
Founded in 1938 and listed on NASDAQ since 1993, Hawkins operates within the GICS Materials sector, specifically the Commodity Chemicals sub-industry. Its business model blends chemical distribution with specialty formulation and on-site water management services, generating revenue through both product sales and recurring service contracts with municipal and industrial clients.
- Water Treatment segment drives margin expansion from infrastructure demand
- Specialty chemical raw material costs pressure gross margins
- Acquisition pipeline in food ingredients accelerates revenue growth
| Net Income: 81.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -0.50 > 1.0 |
| NWC/Revenue: 11.68% < 20% (prev 12.68%; Δ -1.00% < -1%) |
| CFO/TA 0.14 > 3% & CFO 144.3m > Net Income 81.5m |
| Net Debt (275.0m) to EBITDA (175.4m): 1.57 < 3 |
| Current Ratio: 2.21 > 1.5 & < 3 |
| Outstanding Shares: last quarter (20.9m) vs 12m ago 0.11% < -2% |
| Gross Margin: 22.61% > 18% (prev 22.78%; Δ -0.17% > 0.5%) |
| Asset Turnover: 122.3% > 50% (prev 126.6%; Δ -4.23% > 0%) |
| Interest Coverage Ratio: 9.10 > 6 (EBIT TTM 122.8m / Interest Expense TTM 13.5m) |
| A: 0.13 (Total Current Assets 231.5m - Total Current Liabilities 104.8m) / Total Assets 1.00b |
| B: 0.50 (Retained Earnings 500.1m / Total Assets 1.00b) |
| C: 0.14 (EBIT TTM 122.8m / Avg Total Assets 885.8m) |
| D: 1.14 (Book Value of Equity 534.0m / Total Liabilities 467.7m) |
| Altman-Z'' = 4.59 = AA |
| DSRI: 0.94 (Receivables 140.7m/134.7m, Revenue 1.08b/974.4m) |
| GMI: 1.01 (GM 22.78% / 22.61%) |
| AQI: 1.25 (AQ_t 0.49 / AQ_t-1 0.39) |
| SGI: 1.11 (Revenue 1.08b / 974.4m) |
| TATA: -0.06 (NI 81.5m - CFO 144.3m) / TA 1.00b) |
| Beneish M = -2.85 (Cap -4..+1) = A |
As of July 29, 2026, the stock is trading at USD 140.39 with a total of 195,619 shares traded. Over the past week, the price has changed by -3.37%, over one month by -0.71%, over three months by -17.67% and over the past year by -12.27%.
Current recommended Stop Loss: 126.30 (which is 10% or 2.4 ATR below the current price).
Hawkins has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy HWKN.
- StrongBuy: 0
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 184.5 | 31.4% |
P/E Trailing = 36.6658
P/E Forward = 32.1543
P/S = 2.6879
P/B = 5.6051
P/EG = 2.4715
Revenue TTM = 1.08b USD
EBIT TTM = 122.8m USD
EBITDA TTM = 175.4m USD
Long Term Debt = 244.0m USD (from longTermDebt, last quarter)
Short Term Debt = 3.00m USD (from shortTermDebt, last quarter)
Debt = 278.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 17.5m
Net Debt = 275.0m USD (calculated: Debt 278.9m - CCE 3.91m)
Enterprise Value = 3.19b USD (2.91b + Debt 278.9m - CCE 3.91m)
Interest Coverage Ratio = 9.10 (Ebit TTM 122.8m / Interest Expense TTM 13.5m)
EV/FCF = 37.03x (Enterprise Value 3.19b / FCF TTM 86.1m)
FCF Yield = 2.70% (FCF TTM 86.1m / Enterprise Value 3.19b)
FCF Margin = 7.94% (FCF TTM 86.1m / Revenue TTM 1.08b)
Net Margin = 7.52% (Net Income TTM 81.5m / Revenue TTM 1.08b)
Gross Margin = 22.61% ((Revenue TTM 1.08b - Cost of Revenue TTM 838.6m) / Revenue TTM)
Gross Margin QoQ = 20.40% (prev 20.82%)
Tobins Q-Ratio = 3.18 (Enterprise Value 3.19b / Total Assets 1.00b)
Interest Expense / Debt = 4.84% (Interest Expense 13.5m / Debt 278.9m)
Taxrate = 25.42% (27.8m / 109.3m)
NOPAT = 91.6m (EBIT 122.8m * (1 - 25.42%))
Current Ratio = 2.21 (Total Current Assets 231.5m / Total Current Liabilities 104.8m)
Debt / Equity = 0.52 (Debt 278.9m / totalStockholderEquity, last quarter 534.0m)
Debt / EBITDA = 1.57 (Net Debt 275.0m / EBITDA 175.4m)
Debt / FCF = 3.19 (Net Debt 275.0m / FCF TTM 86.1m)
Total Stockholder Equity = 511.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 9.21% (Net Income 81.5m / Total Assets 1.00b)
RoE = 15.95% (Net Income TTM 81.5m / Total Stockholder Equity 511.1m)
RoCE = 16.27% (EBIT 122.8m / Capital Employed (Equity 511.1m + L.T.Debt 244.0m))
RoIC = 10.23% (NOPAT 91.6m / Invested Capital 895.9m)
WACC = 7.31% (E(2.91b)/V(3.19b) * Re(7.66%) + D(278.9m)/V(3.19b) * Rd(4.84%) * (1-Tc(0.25)))
Discount Rate = 7.66% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -71.74 | Cagr: -0.08%
[DCF] Terminal Value 77.97% ; FCFF base≈79.7m ; Y1≈91.3m ; Y5≈134.4m
[DCF] Fair Price = 83.57 (EV 2.02b - Net Debt 275.0m = Equity 1.75b / Shares 20.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 84.29 | EPS CAGR: 9.85% | SUE: 0.24 | # QB: 0
Revenue Correlation: 89.20 | Revenue CAGR: 6.11% | SUE: 1.09 | # QB: 1
EPS current Quarter (2026-06-30): EPS=1.53 | Chg30d=+0.00% | Revisions=+25% | Analysts=2
EPS next Quarter (2026-09-30): EPS=1.36 | Chg30d=+0.00% | Revisions=+25% | Analysts=2
EPS current Year (2027-03-31): EPS=4.82 | Chg30d=+0.00% | Revisions=+25% | GrowthEPS=+21.8% | GrowthRev=+7.6%
EPS next Year (2028-03-31): EPS=5.39 | Chg30d=+0.00% | Revisions=+25% | GrowthEPS=+12.0% | GrowthRev=+5.4%
[Analyst] Revisions Ratio: +57% (up=4, down=0)